相关实验视频

Updated: Jul 4, 2025

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method

Published on: August 2, 2021

白质体积和选择性孕激素受体调节剂治疗在患有月经前失调障碍的患者中

Elisavet Kaltsouni¹, Johan Wikström², Rupert Lanzenberger³

¹Department of Women's and Children's Health, Science for Life Laboratory, Uppsala University, Sweden.

Psychoneuroendocrinology

|January 31, 2024

概括

选择性孕激素受体调节器 (SPRM) 治疗对月经前失调障碍 (PMDD) 有好处. 这项研究发现SPRM治疗后白质体积没有变化,这表明白质体积与缓解症状无关.

科学领域:

神经成像是一种神经成像.
神经科学是一个神经科学.
药理学药理学是指药理学的学科.

背景情况:

月经前失调障碍 (PMDD) 是一种情绪障碍.
选择性孕激素受体调节剂 (SPRM) 显示PMDD的治疗效益.
之前的研究发现了PMDD患者和对照人群之间神经变化和白质结构的差异.

研究的目的:

研究PMDD患者白质体积 (WMV) 和SPRM治疗之间的关系.
为了确定SPRM治疗是否会改变PMDD患者的白质体积.

主要方法:

一项药物神经成像研究,涉及PMDD患者在随机对照试验中.
磁共振成像 (MRI) 在用乌利普里斯塔酸盐 (SPRM) 或安慰剂治疗三个月之前和之后进行.
进行了基于voxel的形态学 (vbm) 分析,以评估对wmv的治疗效果.

主要成果:

在任何大脑区域都没有观察到对白质体积的显著治疗时间相互作用效应.
分析的特定白质道包括前丘脑辐射,环膜和上纵囊.
在SPRM治疗三个月后,没有检测到白质体积的变化.

结论:

这项研究首次表明,经过三个月的孕激素对抗,白质体积没有变化.
白质体积似乎没有起到与PMDDSPRM治疗相关的缓解症状的作用.
研究结果表明,SPRMs在PMDD中的治疗效果可能不会通过白质体积的变化来调解.

关键词:

卵巢激素卵巢激素在 PMDD 的情况下,它是 PMDD.孕激素对抗的作用这就是VBM的VBM.白质量体积,白质量体积.

更多相关视频

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

Design and Implementation of an fMRI Study Examining Thought Suppression in Young Women with, and At-risk, for Depression

Design and Implementation of an fMRI Study Examining Thought Suppression in Young Women with, and At-risk, for Depression

Published on: May 19, 2015

相关概念视频

Antidepressant Drugs: MAOIs and Other Agents

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...

Disorders of the Female Reproductive System

Disorders of the Female Reproductive System

The female reproductive system can be affected by several disorders, including Premenstrual Syndrome (PMS), Premenstrual Dysphoric Disorder (PMDD), endometriosis, and various forms of cancer. PMS and PMDD are cyclical conditions that cause physical and emotional distress, with symptoms that include edema, mood swings, and food cravings. PMDD is a more severe form of PMS characterized by increased symptom severity that peaks during the luteal phase and tends to improve or resolve shortly after...